Immunome, Inc. (NASDAQ:IMNM) Given Average Recommendation of “Moderate Buy” by Analysts

Posted by on Jul 6th, 2026

Shares of Immunome, Inc. (NASDAQ:IMNM – Get Free Report) have been given an average recommendation of “Moderate Buy” by the thirteen ratings firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and twelve have given a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $33.1667.

A number of brokerages have commented on IMNM. Truist Financial increased their price objective on shares of Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Immunome in a research report on Wednesday, May 13th. Barclays assumed coverage on shares of Immunome in a research note on Thursday, May 28th. They set an “overweight” rating and a $36.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a report on Tuesday, April 21st. Finally, Leerink Partners dropped their price objective on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research report on Friday, May 15th.

Read Our Latest Research Report on Immunome

Insider Buying and Selling at Immunome

In other news, CFO Max Rosett sold 60,000 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $18.23, for a total value of $1,093,800.00. Following the transaction, the chief financial officer owned 54,037 shares of the company’s stock, valued at $985,094.51. This represents a 52.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Isaac Barchas sold 100,000 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $22.59, for a total value of $2,259,000.00. Following the completion of the transaction, the director owned 208,504 shares in the company, valued at $4,710,105.36. This represents a 32.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 316,050 shares of company stock worth $6,578,726. 7.21% of the stock is currently owned by insiders.

Institutional Trading of Immunome

A number of hedge funds have recently modified their holdings of the company. T. Rowe Price Investment Management Inc. increased its stake in Immunome by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after purchasing an additional 5,003,824 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Immunome by 23.4% in the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock valued at $129,705,000 after buying an additional 1,144,788 shares during the period. Primecap Management Co. CA grew its holdings in shares of Immunome by 55.2% in the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock valued at $100,643,000 after buying an additional 1,667,432 shares during the period. State Street Corp increased its position in shares of Immunome by 37.9% in the 4th quarter. State Street Corp now owns 3,868,000 shares of the company’s stock valued at $83,085,000 after buying an additional 1,064,027 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Immunome by 8,659.2% during the 4th quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after buying an additional 2,823,144 shares during the period. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Price Performance

Shares of Immunome stock opened at $23.61 on Monday. The firm has a market capitalization of $2.67 billion, a PE ratio of -9.92 and a beta of 2.07. The company’s fifty day moving average price is $20.96 and its two-hundred day moving average price is $21.79. Immunome has a 52-week low of $7.96 and a 52-week high of $27.65.

Immunome (NASDAQ:IMNM – Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. Analysts predict that Immunome will post -2.06 earnings per share for the current fiscal year.

Immunome Company Profile

(Get Free Report)

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.

Featured Articles

Analyst Recommendations for Immunome (NASDAQ:IMNM)

Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.